(PCVX) Vaxcyte - Overview

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US92243G1085

Stock:

Total Rating 38
Risk 82
Buy Signal 1.32
Biotechnology +3.0
Biotechnology +1.8
Market Cap: 8,229m
Avg Trading Vol: 65.5M USD
ATR: 4.72%
Peers RS (IBD): 58.00
Risk 5d forecast
Volatility 45.7%
Relative Tail Risk -7.76%
Reward TTM
Sharpe Ratio 0.07
Alpha -48.36
Character TTM
Beta 1.609
Beta Downside 3.342
Drawdowns 3y
Max DD 76.22%
CAGR/Max DD 0.20

EPS (Earnings per Share)

EPS (Earnings per Share) of PCVX over the last years for every Quarter: "2020-12": -0.41, "2021-03": -0.41, "2021-06": -0.46, "2021-09": -0.51, "2021-12": -0.55, "2022-03": -0.68, "2022-06": -0.8, "2022-09": -0.93, "2022-12": -1.02, "2023-03": -0.7, "2023-06": -0.7, "2023-09": -0.91, "2023-12": -1.82, "2024-03": -0.85, "2024-06": -1.1, "2024-09": -0.83, "2024-12": -1.0176, "2025-03": -1.04, "2025-06": -1.22, "2025-09": -1.56, "2025-12": 0,
EPS CAGR: 12.43%
EPS Trend: -2.9%
Last SUE: 4.00
Qual. Beats: 1

Revenue

Revenue of PCVX over the last years for every Quarter: 2020-12: 0, 2021-03: 0, 2021-06: 0, 2021-09: 0, 2021-12: 0, 2022-03: 0, 2022-06: 0, 2022-09: 0, 2022-12: 0, 2023-03: 0, 2023-06: 0, 2023-09: 0, 2023-12: 14.446, 2024-03: 0, 2024-06: 0, 2024-09: 0, 2024-12: 0, 2025-03: 0, 2025-06: 0, 2025-09: 0, 2025-12: null,
Rev. CAGR: 0.00%
Rev. Trend: 2.8%
Last SUE: 0.00
Qual. Beats: 0

Description: PCVX Vaxcyte

Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; and VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM)
FCF/TA: -0.19 > 0.02 and ΔFCF/TA -1.16 > 1.0
NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev)
CFO/TA -0.17 > 3% & CFO -542.1m > Net Income -657.2m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 8.83 > 1.5 & < 3
Outstanding Shares: last quarter (136.2m) vs 12m ago 10.11% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 0.0% > 50% (prev 0.41%; Δ -0.41% > 0%)
Interest Coverage Ratio: -15.58 > 6 (EBITDA TTM -599.8m / Interest Expense TTM 39.6m)

Altman Z'' -7.14

A: 0.49 (Total Current Assets 1.77b - Total Current Liabilities 200.0m) / Total Assets 3.17b
B: -0.60 (Retained Earnings -1.91b / Total Assets 3.17b)
C: -0.18 (EBIT TTM -617.6m / Avg Total Assets 3.37b)
D: -6.84 (Book Value of Equity -1.91b / Total Liabilities 278.7m)
Altman-Z'' Score: -7.14 = D

Beneish M

DSRI: none (Receivables 400.0k/17.9m, Revenue 0.0/14.4m)
GMI: 1.00 (fallback, negative margins)
AQI: 1.09 (AQ_t 0.34 / AQ_t-1 0.31)
SGI: none (Revenue 0.0 / 14.4m)
TATA: -0.04 (NI -657.2m - CFO -542.1m) / TA 3.17b)
Beneish M-Score: cannot calculate (missing components)

What is the price of PCVX shares?

As of February 26, 2026, the stock is trading at USD 63.04 with a total of 2,222,520 shares traded.
Over the past week, the price has changed by +12.23%, over one month by +18.05%, over three months by +25.48% and over the past year by -20.55%.

Is PCVX a buy, sell or hold?

Vaxcyte has received a consensus analysts rating of 4.90. Therefore, it is recommended to buy PCVX.
  • StrongBuy: 9
  • Buy: 1
  • Hold: 0
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the PCVX price?

Issuer Target Up/Down from current
Wallstreet Target Price 102.1 62%
Analysts Target Price 102.1 62%

PCVX Fundamental Data Overview February 21, 2026

P/B = 2.7874
Revenue TTM = 0.0 USD
EBIT TTM = -617.6m USD
EBITDA TTM = -599.8m USD
Long Term Debt = 84.4m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 5.77m USD (from shortTermDebt, last quarter)
Debt = 84.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -196.6m USD (from netDebt column, last quarter)
Enterprise Value = 6.60b USD (8.23b + Debt 84.4m - CCE 1.71b)
Interest Coverage Ratio = -15.58 (Ebit TTM -617.6m / Interest Expense TTM 39.6m)
EV/FCF = -11.16x (Enterprise Value 6.60b / FCF TTM -591.5m)
FCF Yield = -8.96% (FCF TTM -591.5m / Enterprise Value 6.60b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 4.99m) / Revenue TTM)
Tobins Q-Ratio = 2.08 (Enterprise Value 6.60b / Total Assets 3.17b)
Interest Expense / Debt = 12.71% (Interest Expense 10.7m / Debt 84.4m)
Taxrate = 21.0% (US default 21%)
NOPAT = -487.9m (EBIT -617.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.83 (Total Current Assets 1.77b / Total Current Liabilities 200.0m)
Debt / Equity = 0.03 (Debt 84.4m / totalStockholderEquity, last quarter 2.89b)
Debt / EBITDA = 0.33 (negative EBITDA) (Net Debt -196.6m / EBITDA -599.8m)
Debt / FCF = 0.33 (negative FCF - burning cash) (Net Debt -196.6m / FCF TTM -591.5m)
Total Stockholder Equity = 3.12b (last 4 quarters mean from totalStockholderEquity)
RoA = -19.53% (Net Income -657.2m / Total Assets 3.17b)
RoE = -21.08% (Net Income TTM -657.2m / Total Stockholder Equity 3.12b)
RoCE = -19.29% (EBIT -617.6m / Capital Employed (Equity 3.12b + L.T.Debt 84.4m))
RoIC = -15.65% (negative operating profit) (NOPAT -487.9m / Invested Capital 3.12b)
WACC = 11.82% (E(8.23b)/V(8.31b) * Re(11.84%) + D(84.4m)/V(8.31b) * Rd(12.71%) * (1-Tc(0.21)))
Discount Rate = 11.84% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 14.20%
[DCF] Fair Price = unknown (Cash Flow -591.5m)
EPS Correlation: -2.86 | EPS CAGR: 12.43% | SUE: 4.0 | # QB: 1
Revenue Correlation: 2.80 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-1.53 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=2
EPS next Year (2026-12-31): EPS=-6.18 | Chg7d=+0.038 | Chg30d=+0.038 | Revisions Net=-2 | Growth EPS=-17.1% | Growth Revenue=+0.0%
[Analyst] Revisions Ratio: -1.00 (0 Up / 1 Down within 30d for Next Quarter)

Additional Sources for PCVX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Fund Manager Positions: Dataroma | Stockcircle